Podcasts about pcv2

SwineCast 1239 Show Notes: The Swine Disease Reporting System team features special guest Dr. Pablo Pineyro (Iowa State University) to discuss discusses PCV2 monitoring strategies. This SwineCast episode shares the most recent report number 64, that can also be found at https://fieldepi.research.cvm.iastate.edu/sdrs/.

Prof Hans Nauwynck is attached to the Faculty of Veterinary Medicine at Ghent University in Belgium. Viral diseases are at the core of his attention – and they will take centre stage in this episode of “Meet the Expert”. He will discuss reproductive failure in pigs, with particular attention for the viral component of that problem: PCV2, PRRS virus and parvovirus will be discussed.

In this episode we welcome Dr Marina Sibila from the animal research institute CReSA-IRTA in Catalunya, Spain. Her research line focuses mainly on the epidemiology, diagnosis, animal model development and prevention/treatment strategies of porcine respiratory pathogens, mainly porcine circoviruses (PCV-2 and PCV-3) and porcine mycoplasmas. With Dr Sibila we shall discuss the diagnostics of Porcine Circovirus – type 2.

Dr. Aljets's primary areas of focus are swine production medicine and sow farm management. Thus, he highlights that PCV2 is probably much more complicated than we realize. It is, therefore, necessary to continue discussing and researching this disease. Have you ever had a PCV-2 outbreak on your pig farm?

Uno de los grandes desafíos que enfrentamos en la producción porcina, está relacionado con la salud de los cerdos. Las enfermedades infecciosas virales generan impactos económicos devastadores y su control efectivo es motivo de gran preocupación para la comunidad científica que trata de dar respuestas. El Circovirus Porcino 3 (PCV3), es un virus que se detectó en animales que mostraban fallo reproductivo, inflamación multisistémica y síndrome de la dermatitis y nefropatía porcina (PDNS); desde entonces, se ha encontrado en cerdos de todo el mundo, con o sin manifestaciones clínicas; y a pesar que existen algunas vacunas, es necesario seguir investigando para determinar una clara definición de caso y su impacto económico. Los que vas a aprender: ¿Qué sabemos sobre la infección por Circovirus Porcino 3 (PCV3)? Relación con el Circovirus porcino tipo 2 (PCV2). Importancia de la genotipificación en el control efectivo de este agente. Aspectos claves sobre la vacunación para PCV2. ¿Qué desafíos nos trae la presentación subclínica? Nuestro Invitado: El Dr. Pablo Piñeyro es un reconocido investigador en diagnóstico patológico en la industria porcina. Se tituló como Médico Veterinario en la Universidad de La Plata en Argentina, para luego realizar una maestría en Ciencias Veterinarias en Washington State University y un doctorado en el mismo campo, en la Universidad de La Plata. También cuenta con un doctorado en Ciencias Biomédicas en el Virginia Polytechnic Institute and State University. Actualmente se desempeña como profesor asociado y patólogo en Iowa State University, donde realiza intensa investigación sobre PCV2, PCV3, PRRSV y IAV.

“La presencia global del PCV2, los avances en la investigación de la enfermedad y la eficacia de las vacunas disponibles, han permitido disminuir la presión de infección en las granjas; sin embargo, el fuerte impacto económico de la infección subclínica, requiere de la implementación de estrategias que se adecuen al manejo de cada granja” Los que vas a aprender: Nuevas estrategias en la vacunación frente a PCV2 Epidemiología del PCV2: ¿Cómo ha ido evolucionando en el tiempo? Impacto de la infección subclínica en la productividad de los cerdos Consideraciones para evaluar la eficacia vacunal. Importancia del diagnóstico en el control de PCV2 Nuestro invitado: El Dr. Joaquim Segalés se licenció en la Facultad de Veterinaria de la Universidad Autónoma de Barcelona (UAB), en donde también realizó el doctorado en Medicina y Sanidad Animal. Cuenta con más de 25 años de experiencia realizando investigación aplicada a enfermedades infecciosas en porcinos, con énfasis en PCV2. Actualmente se desempeña como profesor asociado en la UAB e investigador en el Centre de Recerca en Sanitat Animal (CReSA).

“So far, all vaccines in the market have shown great efficacy in reducing clinical signs associated to diseases caused by PCV-2, independently of the genotype present in the farm. Moreover, experimental data demonstrated the cross-protection of PCV-2a vaccines against the most widespread genotypes (PCV-2a, PCV-2b, and PCV-2d). Therefore, despite the significant number of genotypes described/proposed (PCV-2a to PCV-2i), it seems one single PCV-2 serotype would exist". Joaquim Segalés is full professor at the UAB and researcher at the IRTA-CReSA animal health research institute. He has been working with swine diseases for the last 28 years and he has also been working with zoonotic coronaviruses since 2014. He is co-author of more than 350 peer-reviewed publications, most of them on pig diseases and specifically on porcine circovirus diseases. Professor Segalés will share his wealth of experience on the evolution of the PCV2 virus and what that means in terms of diagnosis, understanding the evolving epidemiology and the control using vaccines. How can we make the right decisions on the farm?

A circovirose (PCV2) é um grande desafio para a produção de suínos, pois abre portas para doenças secundárias e agrava o quadro. Neste bate-papo, o especialista em Marketing Bruno Freitas e o médico-veterinário e professor da UNESP de Jaboticabal (SP), Luís Guilherme de Oliveira, falam sobre essa doença que se caracteriza por ser multifatorial.   Aproveite para conferir o nosso programa de TV, o Ourofino em Campo, nas telas do Terra Viva, aos sábados, às 9h30 (horário de Brasília), e de segunda a sexta, às 12h30 e 20h20.    Quer falar com a gente? Nosso "Zap" é o (16) 98181-8687.

No episódio de hoje, o Prof. Dr. Fábio Vannucci nos atualiza sobre o PCV3, novo vírus que afeta suínos identificado em 2016, da mesma família do PCV2. Confira nosso episódio e se informe sobre esse recente desafio para a suinocultura! Dr. Fábio Vannucci - Médico veterinário pela Universidade Federal de Viçosa em 2006. Mestrado em patologia animal em 2009 pela Universidade Federal de Minas Gerais. Doutorado em doenças infecciosas pela Universidade de Minnesota 2013. Atualmente, professor e patologista no Laboratório de Diagnóstico Veterinário da Universidade de Minnesota. Área de atuação com ênfase em diagnóstico de doenças de suínos.

A clinical outbreak of porcine circovirus type 2 (PCV2) occurred this past winter in otherwise healthy, well-vaccinated herds, Clayton Johnson, DVM, of Carthage Veterinary Service, told Pig Health Today. The post It’s back: Clinical outbreak of PCV2 in genetic herds reported appeared first on Pig Health Today.

A clinical outbreak of porcine circovirus type 2 (PCV2) occurred this past winter in otherwise healthy, well-vaccinated herds, Clayton Johnson, DVM, of Carthage Veterinary Service, told Pig Health Today. The post It's back: Clinical outbreak of PCV2 in genetic herds reported appeared first on Pig Health Today.

Genetic sequencing demonstrates that porcine circovirus type 3 (PCV3) is significantly different from PCV2, but otherwise little is known about the virus. The post Tale of two viruses: PCV3 impact unknown while PCV2 continues to evolve appeared first on Pig Health Today.

Genetic sequencing demonstrates that porcine circovirus type 3 (PCV3) is significantly different from PCV2, but otherwise little is known about the virus. The post Tale of two viruses: PCV3 impact unknown while PCV2 continues to evolve appeared first on Pig Health Today.

What is “cell-mediated immunity” and how does it affect vaccine performance? Are two PCV2 genotypes necessarily better than one? And what does a monster from Greek mythology have to do with building a better vaccine? The post Scientist ‘pops the hood’ on US pork industry’s newest vaccine for PCV2 appeared first on Pig Health Today.

What is “cell-mediated immunity” and how does it affect vaccine performance? Are two PCV2 genotypes necessarily better than one? And what does a monster from Greek mythology have to do with building a better vaccine? The post Part 1: Cell-mediated immunity critical to vaccine performance appeared first on Pig Health Today.

What is “cell-mediated immunity” and how does it affect vaccine performance? Are two PCV2 genotypes necessarily better than one? And what does a monster from Greek mythology have to do with building a better vaccine? The post Part 2: Why two PCV2 genotypes are better than one appeared first on Pig Health Today.

What is “cell-mediated immunity” and how does it affect vaccine performance? Are two PCV2 genotypes necessarily better than one? And what does a monster from Greek mythology have to do with building a better vaccine? The post Part 3: Chimeric vaccines combine strengths of each antigen to provide better coverage appeared first on Pig Health Today.

What is “cell-mediated immunity” and how does it affect vaccine performance? Are two PCV2 genotypes necessarily better than one? And what does a monster from Greek mythology have to do with building a better vaccine? The post Part 2: Why two PCV2 genotypes are better than one appeared first on Pig Health Today.

What is “cell-mediated immunity” and how does it affect vaccine performance? Are two PCV2 genotypes necessarily better than one? And what does a monster from Greek mythology have to do with building a better vaccine? The post Part 1: Cell-mediated immunity critical to vaccine performance appeared first on Pig Health Today.

What is “cell-mediated immunity” and how does it affect vaccine performance? Are two PCV2 genotypes necessarily better than one? And what does a monster from Greek mythology have to do with building a better vaccine? The post Scientist ‘pops the hood' on US pork industry's newest vaccine for PCV2 appeared first on Pig Health Today.

What is “cell-mediated immunity” and how does it affect vaccine performance? Are two PCV2 genotypes necessarily better than one? And what does a monster from Greek mythology have to do with building a better vaccine? The post Part 3: Chimeric vaccines combine strengths of each antigen to provide better coverage appeared first on Pig Health Today.

SwineCast 1037 Show Notes: In this episode of At the Meeting honoring Dr. Bob Morrison, we share a conversation on porcine circovirus 3, or PCV3. Dr. Montse Torremorell joins Dr. Tom Wetzel and Dr. Gordon Spronk with special guest Dr. Darin Madson, Iowa State University, to talk about porcine circovirus 3 and how it is both similar to, and different from PCV2. Dr. Madson and the show's cohosts discuss clinical signs associated with PCV3, including myocarditis, respiratory issues, and reproductive problems, as well as how current research is focused on better understanding the virus, its history, and whether any current PCV vaccines could offer some form of cross-protection. #mc_embed_signup{background:#fff; clear:left; font:14px Helvetica,Arial,sans-serif; } /* Add your own MailChimp form style overrides in your site stylesheet or in this style block. We recommend moving this block and the preceding CSS link to the HEAD of your HTML file. */ Learn From SwineCast

Anyone involved in raising pigs is aware of PCV2, but new on the scene is porcine circovirus type 3 (PCV3). Although the two viruses are both circular DNA viruses in the same family, they are separate and distinct. The post PCV3: A challenge independent from PCV2 appeared first on Pig Health Today.

Anyone involved in raising pigs is aware of PCV2, but new on the scene is porcine circovirus type 3 (PCV3). Although the two viruses are both circular DNA viruses in the same family, they are separate and distinct. The post PCV3: A challenge independent from PCV2 appeared first on Pig Health Today.

Vaccines for porcine circovirus type 2 (PCV2) currently do an adequate job of cross protecting against new genotypes of the virus, but swine veterinarians and producers shouldn’t let their guard down. The post Don’t get complacent with evolving PCV2 virus appeared first on Pig Health Today.

Vaccines for porcine circovirus type 2 (PCV2) currently do an adequate job of cross protecting against new genotypes of the virus, but swine veterinarians and producers shouldn't let their guard down. The post Don't get complacent with evolving PCV2 virus appeared first on Pig Health Today.

Sat, 18 Jul 2015 12:00:00 +0100 https://edoc.ub.uni-muenchen.de/18841/ https://edoc.ub.uni-muenchen.de/18841/1/Koeppen_Marion.pdf Köppen, Marion

SwineCast 0863 Show Notes: The Morrison Group reviews research and experiences in sow herd vaccination impact on PCV2 (Porcine Circovirus Type 2) vertical transmission in this episode of At The Meeting.  (Episode 3 of 3) GUESTS: Dr. Jessica Seate, Murphy-Brown LLC Dr. Dave Baumert, Cargill Pork Dr. Brian Payne, Boehringer Ingelheim Vetmedica Research papers: “Management Characteristics of PCV2 PUCS Stable Sow Herds” by Jessica Seate, Tom Fangman, Al Scheidt, Brian Payne. ESPHM 2015 Proceedings and ISERPD 2015 Proceedings “Assessing Sow Herd PCV2 Stability and Vertical Transmission Utilizing Colostrum and Placental Umbilical Cord Serum,” by Jessica Seate, Darin Madson, Al Sheidt, Brian Payne. ESPHM 2015 Proceedings and ISERPD 2015 Proceedings “Commercial PCV2a-based vaccines are effective in protecting naturally PCV2b-infected finisher pigs against experimental challenge with a 2012 mutant PCV2” by Tanja Opriessnig, Priscilla F. Gerber, Chao-Ting Xiao, Patrick G. Halbur, Shannon R. Matzinger, Xiang-Jin Meng. Vaccine 32 (2014) 4342-4348 “Complete Genome Sequence of a Novel Porcine Circovirus Type 2b Variant Present in Cases of Vaccine Failures in the United States” by Chao-Ting Xiao, Patrick G. Halbur, Tanja Opriessnig. Journal of Virology 86 (2012) 12469 “Porcine Circovirus type 2 (PCV2) infections: Clinical signs, pathology and laboratory diagnosis” by Joaquim Segalés. Virus Research 164 (2012) 10-19 “The effect of commercial combination PCV2/Mycoplasma hyopneumoniae vaccination products on wean to finish performance” by Brian Payne, Greg Cline. IPVS 2012 Proceedings

SwineCast 0862 Show Notes: The Morrison Group discusses PCV2 (Porcine Circovirus Type 2) vaccines and industry impact in this episode of At The Meeting.  (Episode 2 of 3) GUESTS: Dr. Jessica Seate, Murphy-Brown LLC Dr. Dave Baumert, Cargill Pork Dr. Brian Payne, Boehringer Ingelheim Vetmedica Research papers: “Management Characteristics of PCV2 PUCS Stable Sow Herds” by Jessica Seate, Tom Fangman, Al Scheidt, Brian Payne. ESPHM 2015 Proceedings and ISERPD 2015 Proceedings “Assessing Sow Herd PCV2 Stability and Vertical Transmission Utilizing Colostrum and Placental Umbilical Cord Serum,” by Jessica Seate, Darin Madson, Al Sheidt, Brian Payne. ESPHM 2015 Proceedings and ISERPD 2015 Proceedings “Commercial PCV2a-based vaccines are effective in protecting naturally PCV2b-infected finisher pigs against experimental challenge with a 2012 mutant PCV2” by Tanja Opriessnig, Priscilla F. Gerber, Chao-Ting Xiao, Patrick G. Halbur, Shannon R. Matzinger, Xiang-Jin Meng. Vaccine 32 (2014) 4342-4348 “Complete Genome Sequence of a Novel Porcine Circovirus Type 2b Variant Present in Cases of Vaccine Failures in the United States” by Chao-Ting Xiao, Patrick G. Halbur, Tanja Opriessnig. Journal of Virology 86 (2012) 12469 “Porcine Circovirus type 2 (PCV2) infections: Clinical signs, pathology and laboratory diagnosis” by Joaquim Segalés. Virus Research 164 (2012) 10-19 “The effect of commercial combination PCV2/Mycoplasma hyopneumoniae vaccination products on wean to finish performance” by Brian Payne, Greg Cline. IPVS 2012 Proceedings

SwineCast 0861 Show Notes: The Morrison Group discusses Diagnostics and Clinical Signs of PCV2 (Porcine Circovirus Type 2) in this episode of At The Meeting.  (Episode 1 of 3) GUESTS: Dr. Albert Rovira, Veterinary Diagnostic Lab, University of Minnesota Dr. Jessica Seate, Murphy-Brown LLC Dr. Dave Baumert, Cargill Pork Dr. Brian Payne, Boehringer Ingelheim Vetmedica Research papers: “Management Characteristics of PCV2 PUCS Stable Sow Herds” by Jessica Seate, Tom Fangman, Al Scheidt, Brian Payne. ESPHM 2015 Proceedings and ISERPD 2015 Proceedings “Assessing Sow Herd PCV2 Stability and Vertical Transmission Utilizing Colostrum and Placental Umbilical Cord Serum,” by Jessica Seate, Darin Madson, Al Sheidt, Brian Payne. ESPHM 2015 Proceedings and ISERPD 2015 Proceedings “Commercial PCV2a-based vaccines are effective in protecting naturally PCV2b-infected finisher pigs against experimental challenge with a 2012 mutant PCV2” by Tanja Opriessnig, Priscilla F. Gerber, Chao-Ting Xiao, Patrick G. Halbur, Shannon R. Matzinger, Xiang-Jin Meng. Vaccine 32 (2014) 4342-4348 “Complete Genome Sequence of a Novel Porcine Circovirus Type 2b Variant Present in Cases of Vaccine Failures in the United States” by Chao-Ting Xiao, Patrick G. Halbur, Tanja Opriessnig. Journal of Virology 86 (2012) 12469 “Porcine Circovirus type 2 (PCV2) infections: Clinical signs, pathology and laboratory diagnosis” by Joaquim Segalés. Virus Research 164 (2012) 10-19 “The effect of commercial combination PCV2/Mycoplasma hyopneumoniae vaccination products on wean to finish performance” by Brian Payne, Greg Cline. IPVS 2012 Proceedings

Sat, 31 Jan 2015 12:00:00 +0100 https://edoc.ub.uni-muenchen.de/17946/ https://edoc.ub.uni-muenchen.de/17946/1/Szikora_Florian.pdf Szikora, Florian

The aim of this study was to describe the serological course of H. parasuis in three farms during a present coinfection with M. hyorhinis, PRRSV and PCV2. The examinations occurred in three breeding farms and their complementary finishing units. A clinical examination and blood sampling was done in regular two-week intervals of animals from the 1st to the 11th week of life and the same was done with animals between the 14th and 22nd week of life but in four-week intervals. Furthermore, blood samples were taken from sows in the first week after farrowing. The detection of antibodies against H. parasuis, M. hyorhinis, PCV2 and PRRSV was done using ELISA. The increased lameness that was seen in farm 1 from the 14th week of life was due to H. parasuis because of a simultaneous occurrence in the rise of the antibody titer and the seroprevalence for H. parasuis. In the second and third farm, H. parasuis probably played a role as a cofactor in the porcine respiratory disease complex (PRDC). A correspondent increase in the age of the animals and the clinical scores could be detected for all three farms. In addition, an increase in the occurrence of multiple infections was observed during the finishing period. Double and single infections were present in most of the examined animals, and PCV2 was involved in all cases. Antibodies against PCV2 were found in all animals at the end of the finishing period. A significant association was detected for the mutual occurrence of H. parasuis and PCV2 in the 18th week of life. A synergism of both agents cannot be fully ascertained because of the time at which the significant mutual detection occurred. The tendency of both PCV2 and PRRSV to mutually occur was observed but a significant association was not found. A significant correlation between the antibodies of the sows and their piglets was found for all examined agents in the first week of life. In the first week of life, identical antibody titers for H. parasuis were measured in the sows and piglets and the PRRSV and PCV2 antibody titers of the piglets were even higher in the first week of life. The drop in the antibody titer in the following week of life depended on the specific agent and the starting antibody titer of the piglet in the first week of life. This fall was prolonged if the antibody titer in the first week of life was very high. High antibody titers in the sows are a prerequisite for a good passive immunity in piglets in the first week of life. The maternal immunity against H. parasuis, PRRSV and PCV2 can be improved by sow vaccination. No uniform seroconversion time was found for the four examined agents in the three farms. Thus the seroconversion of H. parasuis and M. hyorhinis began in the ninth and eleventh week of life; PCV2 began in the 9th, 11th, 18th week and PRRSV in the 14th and 18th week of life. Therefore a farm specific serological profile for every relevant agent should be done. In farm 2 and also in farm 3, a mutual seroconversion time in the 9th and 11th week of life was detected for H. parasuis, M. hyorhinis and PCV2. This points to a mutual infection time for these three agents at different times in the respective farms. A simultaneous seroconversion for PRRSV and PCV2 in the 18th week of life was observed in farm 1. Mutual agent influence is possible for H. parasuis, M. hyorhinis and PCV2 and probable for PRRSV and PCV2. The present study demonstrates the difficulty of the interpretation of serological profiles and indicates that an appropriate interpretation of the serological profile can only be done when the clinical signs are also taken into consideration.

The goal of this study was to examine the suitability of five disease agents that are essential in swine production, in a health monitoring program. Not only the selected disease agents and the diagnostic methods were examined but also the sample size. Four market trading companies from Lower Saxony and Schleswig-Holstein provided 38 farrowing farms for the study, and sampling was done on a quarterly basis. Fifteen blood samples were taken from sows every time and serologically examined for Salmonella and in one quarter only PCV2 was tested. A total of fifteen blood samples from feeder pigs were serologically examined for Salmonella in the first and second quarter. In the course of the following testings, instead of blood probes 20 faecal samples were pooled to create four samples which were bacteriologically examined. Additionally, 30 blood probes from three growing stages were examined for antibodies against PCV2 using Ingezim PCV IgG/IgM ELISA. Twenty nasal swabs were pooled to create four samples that were tested for the EU and US strains of PRRSV. Furthermore, the four pooled faecal samples were examined for Brachyspira spp. using Multiplex-PCR, and the probes from the first two quarters were also examined for Campylobacter spp.. The farms were assigned into one of four categories, 0 to 3, based on their results from the serological examination for Salmonella and similar to those of the Salmonella VO and QS. Based on the sow results, 10.8% of the farms were in the category 0, 67% in the category 1 and the rest of the farms fell into the categories 2 and 3. Feeder pigs from three farms were placed in the category 1 and the rest were assigned the category 0. In the following bacteriological examination, Salmonella was identified in ten farms. The bacteriological examination method was better in the flatdeck when compared to the serological method. The serological examination of the sows proved to be effective for a health monitoring program. Antibodies for PCV2 were found in the sows in all farms, which confirms its ubiquitous distribution. No seroconversion could be identified in the weaner-to-feeder pigs in 10 farms. Many farms began piglet vaccination during the project. It was noted that the vaccination influenced the results of the Ingezim ELISA in these farms and that an examination is not necessary. This test can be well implemented in a monitoring program in farms that do not vaccinate. However, this test also identifies maternal antibodies and this needs to be taken into consideration when interpreting results. B. hyodysenteriae could not be identified in any farms. Other Brachyspira species that occur in swine could not be identified with the exception of B. innocens that was found in two farms. PCR appears to be a suitable diagnostic tool for a health monitoring program. The examination for Campylobacter spp. showed a wider distribution of C. coli, and 89.4% of the farms tested positive. C. jejuni could only be found as a coinfection with C. coli in one farm. In four farms, no Campylobacter sp. could be identified. In this case, PCR is also suitable for examining faecal samples. The outcome of the PRRSV examination showed highly differing results in every test period. 78.9 % of the farms altered their status during the project. This infers that the sample size was inadequate in order to determine the actual status of the farm. Moreover, a significant correlation between vaccine strain and the PCR results was observed. The PCR only differentiated between both genotypes but not between field and vaccine strains. However, a differentiation is advisable for a health monitoring program. Alternatively, the examination for PRRSV-free nucleus farms could be restricted and simply the vaccine status could be documented in other production units.

Efficacy of an inactivated one-shot piglet vaccine at either one or three weeks of age with Porcilis® PCV against porcine circovirus type 2 (PCV2) at two farms in southern Germany

The objective of this study was to assess the efficacy of Porcilis® PCV administered as a single dose to piglets at either one or three weeks of age as compared to a placebo group that received Diluvac® Forte twice by injection.